As of late, it has definitely been a great time to be an investor in Kodiak Sciences

KOD earnings call for the period ending March 31, 2020.

Some biotech stocks have contributed materially to the Nasdaq's 1000-point gain since Aug 27, 2018 and helped it notch a record 9,000 on Dec 26.

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2019.

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced promising safety, efficacy and durability data from the ongoing Phase 1b study of its investigational therapy KSI-301, an intravitreal anti-VEGF antibody biopolymer conjugate, in patients with treatment-naïve wet age-related macular degeneration (AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO).

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced today that management will present at the following upcoming investor conferences:

Wall Street is littered with unicorns this past year that have been less than magical for investors. These startups that were valued at over a billion dollars in the private market, couldn’t quite live up to lofty expectations when they finally hit the public market.  AdvisorShares’ CEO Noah Hamman tells Yahoo Finance that he’s focused on building a portfolio of potential unicorns outside of the high flying names, such as the recent initial public offering of Casper (CSPR).  “We are looking for small and micro-cap stocks, which can provide a similar risk return profit as private equity,” says Hamman. “We think it’s a significant area that’s overlooked by investors.”

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]

The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 24.) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Applied ...

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the appointment of Charles Bancroft to its board of directors.

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it will host a business highlights webcast on Tuesday, May 12, 2020 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

These are the biotechnology stocks with the best value, fastest growth, and most momentum for Q2 2020.

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the first quarter ended March 31, 2020.

Small cap stocks are listed companies that have market capitalizations typically ranging from $300 million to $2 billion. Since the share prices of these companies can have big fluctuations over a short period of time, companies with market caps of up to $10 billion are also found in the small cap universe.

This was the fourth time Condon has won honors in one of my contests Continue reading...

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced today that management will present a company overview at the J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 14, 2020 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will present at the virtual Bank of America Merrill Lynch Health Care Conference on Wednesday, May 13, 2020 at 11:20 a.m. Pacific Time (2:20 p.m. Eastern Time).

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that the company received full registration of their trademarks "Kodiak" and "Kodiak Sciences" from the U.S. Patent and Trademark Office for the exclusive use of Kodiak Sciences Inc. and its subsidiaries.

Kodiak Sciences Inc's (NASDAQ: KOD) main drug candidate, KSI-301, highlights the company's focus on innovation in a dynamic treatment landscape, according to Goldman Sachs.The Kodiak Sciences Analyst Graig Suvannavejh initiated coverage of Kodiak Sciences with a Buy rating and a price target of $80.The Kodiak Sciences Thesis Based on a proprietary platform technology, Kodiak Sciences' KSI-301 asset is focused on ophthalmology and is in a pivotal Phase 2/3 trial, with potential in multiple retinal diseases, Suvannavejh said in the note.He cited three main reasons for the bullish rating: 1. Large Commercial Opportunity With Concentrated End-Market: The lead indication for KSI-301 is wet age-related macular degeneration (AMD), which represents a large commercial market, estimated at around $11.5 billion in 2019 global sales for current branded competitors. 2. May mManingfully Reduce Treatment Burden And Improve Outcomes: The current treatments typically require dosage at one- to two-month intervals, causing long wait times for patients and significantly impacting their quality of life. KSI-301 seeks to address this problem by "meaningfully improving the duration of effect for intravitreal injections." So, KSI-301 could push the time between injections to five months or more. 3. Faster Product Approval With Accelerated Clinical Development Timelines: Kodiak Sciences has an aggressive clinical development plan for its lead asset. This plan has been agreed to by the FDA. With the accelerated timelines, KSI-301 could begin generating revenue across multiple indications as early as 2023.KOD Price Action Shares of Kodiak Sciences were trading flat at time of publication Tuesday.Latest Ratings for KOD DateFirmActionFromTo Mar 2020Goldman SachsInitiates Coverage OnBuy Feb 2020BarclaysDowngradesOverweightEqual-Weight Feb 2020SunTrust Robinson HumphreyInitiates Coverage OnBuy View More Analyst Ratings for KOD View the Latest Analyst Ratings See more from Benzinga * JD Shows Resilience Amid Coronavirus Mayhem, UBS Says * Analyst Upgrades RealPage On Solid Results, Constructive Guidance * Wells Fargo Upgrades Trade Desk On 2020 Spend Inflection(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

The old adage of ‘buy low, sell high’ is an oft-repeated mantra in investing circles, and it makes sense, too. There are other investing strategies, though, one of which is momentum investing. This tactic involves buying stocks that have already yielded strong returns in the past few months, with the expectation of further returns to come. Though this type of investing can be risky, the justification for the use of it is made by the claim that far more money is made buying high and selling at even higher prices.The pros on the Street don’t appear averse to it, either; Multinational investment firm Jefferies occupies the third spot on TipRanks’ Top Performing Research Firms ranking, so they must know a thing or two about picking winning stocks.The company recently took note of three interesting momentum stocks. All three posted strong returns in 2019, and according to Jefferies, they are set to continue the trend in 2020. Running each stock through the Stock Screener tool at TipRanks, we’ve confirmed that all presently boast a Strong Buy consensus rating from the Street. Here’s what you need to know about them.Kodiak Sciences (KOD)If you’re about to invest in a momentum stock, then you might as well do so with style. Kodiak Sciences share price grew by over 900% in 2019, the bulk of which occurred in the last two months of the year alone.The retinal disease focused biotech’s surge came off the back of a two-pronged catalyst; (1) The favorable data from a phase 1b study of its lead candidate, KSI-301, a treatment for patients with anti-VEGF wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema due to retinal vein occlusion (RVO), and (2) the positive news that followed: Baker Bros were to purchase a 4.5% royalty right on potential global net sales of the drug in return for a $225 million investment. The investment secures Kodiak’s financial position for the foreseeable future, and acts as an indication of how confident the company is in the drug’s potential to succeed.So, after such a mercurial run up, is it still worth backing Kodiak in 2020? It is, according to Jefferies’ Michael Yee. The 4-star analyst thinks the drug can generate “close to $3-4 billion in peak sales.” Yee noted, “KOD is one of the simpler and more straightforward stories in biotech. We think the primary drug KSI-301 will be highly likely to show strong Phase II/III data in wet AMD and RVO over the next 6-12+ months proving it's much better than current therapies and further de-risking the asset. We see stock going up given data catalysts in 2020-21 and potential M&A optionality.”Yee, therefore, initiated coverage of Kodiak with a Buy rating and a price target of $100, indicating KOD has fuel in the tank for a further gain of nearly 60%. (To watch Yee’s track record, click here)It appears the rest of the Street unanimously agrees with Yee. A Strong Buy consensus rating is formed of solely Buys – 6 to be precise. The average price target comes in at $81.25 and implies upside potential of 30% over the next 12 months. (See Kodiak stock analysis on TipRanks)Vertex Pharmaceuticals (VRTX)Vertex Pharmaceuticals is unique in that it is currently the only company in the world with approved drugs for the treatment of the underlying cause of cystic fibrosis (CF).In October, Vertex’s CF drug, Trikafta, was approved by the FDA. While the company already has other CF treatments on the market, they only serve a small percentage of CF patients. Trikafta, on the other hand, addresses the needs of CF patients with the most common CF causing mutation. More regulatory approvals are projected in Europe, which will further increase Vertex’s market-penetrating potential.While the CF story is one major aspect driving Vertex forward, the company has other treatments in the pipeline, too. These include CRSP CTX-001, a treatment for sickle cell disease, and beta-thalassemia currently in Phase 1/2 trials and VX-814, a treatment for Alpha-1 antitrypsin deficiency, which can cause liver and lung disease. Antitrypsin deficiency treatment represents a potential $3 billion a year market.With Vertex currently trading at 33x future earnings, the question remains as to whether or not the stock is already at a premium. Not yet, according to Jefferies’ Michael Yee, who also covers the large-cap biotech. Yee said, “We think the Trikafta launch will do well and see upside to 2020. Ultimately, revenue should grow from $3.5B towards $9B+ which would create a parabolic ‘earnings cycle’ where EPS could rise from $5 to $12 in the next few years. We think good stories can continue to work and we are optimistic about upside towards $275 this year from a big CF launch but also data from VRTX's pipeline programs.”The 4-star analyst reiterated a Buy recommendation on Vertex alongside the aforementioned price target of $275. Should the target be met, investors will be pocketing a 22% gain over the coming 12 months.Vertex enjoys a healthy following from the Street, with the vast majority on its side; The biotech’s Strong Buy consensus rating breaks down into 19 Buys vs. 3 Holds and is accompanied by an average price target of $239.26. The figure indicates upside potential of ~5%. (See Vertex stock analysis on TipRanks)Gentex Corporation (GNTX)What would you tell someone if they were to ask you, “Should I buy Gentex right now?” After all, Gentex stock is still well off its highs. For Jeffries’ David Kelley the answer is quite clear — the analyst sees this stock as a flower that keeps blossoming.Gentex specializes in a number of areas; along with smoke detectors and signaling devices, Gentex provides dimmable aircraft windows for the aviation markets. The bulk of its business, though, is in the global automotive industry, for which it supplies a variety of products, most notably automatic-dimming rear-view mirrors and camera-based driver assistance systems.Kelley thinks “global production appears poised for a favorable rate of change in 2020 for the first time since 2016” and notes that Gentex’s FDM (Full Display Mirror), a hybrid interior mirror/camera, could have a meaningful impact on revenue. The analyst estimates 33% year-over-year sales growth through 2021.Kelley added, “While most auto supplier estimates appear poised for another round of cuts (although likely lower magnitude vs. '19 revisions) with '20 guidance reveals in January, we believe GNTX is best positioned among our coverage for potential upside surprise given improving revenue outlook & potential margin upside… Scarcity value of production outgrowth remains a key differentiator and thus we see multiple expansion potential.”With “growth inflection approaching” according to Kelley, now is the time for a reevaluation on Gentex. The 4-star analyst upgraded his rating from Hold to Buy in addition to increasing his price target from $27 to $37. This implies upside potential of 22% from current levels. (To watch Kelley’s track record, click here)The rest of the Street is currently rather quiet on Gentex, with only 2 other analysts chiming in with a view on the company’s prospects. Both, though, consider the stock a Buy, and therefore Gentex has a Strong Buy consensus rating. The average price target is $34.33, and suggests 12% upside potential. (See Gentex stock analysis on TipRanks)